Young women in the UAE have higher incidence of HER2 positive breast cancer [ J ]. Breast J, 2012,18 (6) : 637-638.Bashir MA, Ali NA, Shaban S, et al. Young women in the UAE have higher incidence of HER2 positive breast cancer [ J] . Breast J,2012,18(6) :637鄄638....
Patients younger than 40years old and older than 70years old affected by ER(-)/PR(-)/HER2(-) breast cancer have low survival rates: Results of a mono-insti... Objective: The aim of this study is to evaluate the survival and tumor characteristics, including breast cancer phenotypes, of ...
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA t... Several randomised trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer. However, ...
ASHP Midyear: Pharmacists Play Key Role in Addressing Concerns and Fostering Adoption of Biosimilars SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer
Results were consistent in patients with HER2 low expression and HER2 ultralow expression. In the primary endpoint analysis of patients with HR positive, HER2 low metastatic breast cancer, median PFS was 13.2 months in the ENHERTU arm compared to 8.1 months in the chemotherapy arm (HR 0.62; ...
Lupeol has also been shown to inhibit the proliferation of ER+/PR+ and HER2+ breast cancer cells.Additional commentsDespite the similarity in the names, mangosteen (Garcinia mangostana), a Southeast Asian tropical fruit, is not related to mango....
of recurrence, it does not heighten risk of primary breast cancer significantly. Copper has been shown to promote angiogenesis andmetastasis, especially in aggressive forms of breast cancer such as inflammatory (IBC), triple negative (ER-/PR-/HER2-), and HER2 overexpressing (HER2+) breast cancer...
Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evaluated in women with HER2-overexpressing metastatic breast cancer that had progressed after chemotherapy for metastatic disease.Two hundred twenty-two women, with HER2-overexpressing metastatic breast cancer ...
All patients had a preoperative diagnosis of breast cancer and a clinically negative axilla. A subset of the cohort originated from a prospective study evaluating the oncological safety of SNB, the results of which have been published elsewhere (Andersson et al, 2012). The surgery was performed ...
“The PEONY trial adds to the totality of data reinforcing the long-term clinical benefit of adjuvant and neoadjuvant pertuzumab plus trastuzumab with docetaxel in patients with HER2-positive early breast cancer,” Shao concluded. References Shao Z, Pang ...